- Original Research Article
- Open Access
Study the response of Qurevo (ombitasvir, paritaprevir, and ritonavir) in end-stage renal disease patients with hepatitis C virus
Egyptian Liver Journal volume 12, Article number: 36 (2022)
Out of the 185 million people infected with hepatitis C virus (HCV) worldwide according to the World Health Organization (WHO), Egypt had the highest prevalence of HCV reaching 13% of its population with an estimated number of 12 million people. The prevalence of HCV infection among hemodialysis (HD) patients ranged from 6 to 60%. HD patients have an increased overall mortality risk if they have chronic HCV when compared to those without HCV infection. Treatment of HCV with the new direct-acting antiviral agent (DAA) therapy Qurevo “ombitasvir/paritaprevir/ritonavir” with ribavirin in ESRD was approved in many countries compared to traditional HCV treatment that faced restrictions in the setting of chronic kidney disease (CKD).
Aim of the study
To evaluate the efficacy and safety of Qurevo/ribavirin regimen in HCV-infected HD patients.
Patients and methods
A prospective cohort study evaluated the outcome of 12-week ombitasvir (NS5A inhibitor)/paritaprevir (NS3/4A protease inhibitor)/ritonavir with ribavirin combination therapy for 50 HCV-infected HD patients, over a period of 15 months from December 2016 to February 2018. The primary endpoint was sustained virologic response 12 weeks after therapy (SVR12) and after 24 weeks of therapy (SVR24).
The SVR12 rate was 96% (48/50); 2 patients (4%) were non-responders to treatment at SVR12, and another 2 (4%) were relapsers after SVR12. As regards the adverse events, the most frequent were fatigue/asthenia in 44 patients (88%) and worsening anemia (Hb dropped to < 10 g/dl) in 42 patients (84%). GIT upset occurred in 10 patients (20%), sleep disorders in 8 patients (16%), decreased appetite in 8 patients (16%), respiratory distress in 6 patients (12%), headache and dizziness in 6 patients (12%), and muscle spasms in 4 patients (8%). Itching (pruritus) occurred in 3 patients (6%). Death occurred in 4 patients (8%) after SVR24 most probably not due to DAA but may be due to myocardial infarction, pulmonary edema, severe hypotension on hemodialysis sessions, and shock due to blood loss in retroperitoneal hematoma following peritoneal dialysis not related to DAA therapy. Hepatic decompensation, hypersensitivity (angioedema), teratogenicity, and drug interactions did not occur in any patient (0%). Other events occurred in 11 patients (22%). They were parenchymal liver changes in ultrasound at the end of therapy after being normal before therapy (in 3 patients), thrombocytopenia, increased alkaline phosphatase, hiccough, deterioration of hypertension, urinary tract infection, lower limb cellulitis, vaginal bleeding, and chest infection (in 1 patient each). SVR12 was achieved in 100% of patients who had to stop or modify the ribavirin dose; this means that ribavirin absence did not affect the SVR in these patients.
Our results confirm the efficacy of Qurevo “ombitasvir/paritaprevir/ritonavir” with ribavirin combination therapy in ESRD patients (on regular hemodialysis) with HCV infection with anemia as the most frequent adverse event.
People infected with HCV can develop kidney disease as a result of extrahepatic manifestation of HCV or as a disease process independent of the HCV infection. In addition, hemodialysis has been a risk factor for acquiring HCV infection. Several studies have shown that patients on chronic hemodialysis have an increased overall mortality risk if they have chronic HCV (when compared with those on dialysis who do not have HCV). There are some data showing that chronic hepatitis C may be a risk factor for developing renal cell carcinoma. Chronic HCV infection has also been associated with an accelerated course of renal disease in HIV-infected persons. Extrahepatic manifestations related to HCV, including immune complex-related renal disease, can require urgent HCV treatment to resolve or prevent further organ damage .
Chronic HCV infection was rarely treated in patients with end-stage renal disease during the interferon era because of its toxicities and low tolerability. Among the new direct-acting antivirals, sofosbuvir is cleared renally and therefore is not recommended in patients with estimated glomerular filtration rates below 30 ml/min per 1.73 m2. Most other direct-acting antiviral agents are metabolized by the liver, but blood levels of simeprevir and daclatasvir can rise in the setting of severe renal impairment. In contrast, Qurevo (ombitasvir, paritaprevir, ritonavir) undergoes hepatic metabolism and did not require dose adjustment in phase I studies of patients with mild, moderate, or severe renal impairment .
The availability of new DAAs has sparked major enthusiasm for treating HCV-infected patients with renal impairment. Investigators treated HCV-infected patients with stage 4 or 5 renal disease, including patients on hemodialysis, with a 12-week regimen of Qurevo with or without ribavirin. In the preliminary analysis, 10 (100%) of 10 treated patients achieved a sustained virologic response 4 weeks after completion of therapy (SVR4), and no treatment-related serious adverse events occurred . The most common adverse events were anemia (45% of patients), fatigue (35%), diarrhea (25%), and nausea (25%) . Nearly half of the patients had to interrupt or discontinue ribavirin because of worsening anemia in some studies .
Egypt’s Health Ministry approved the new oral interferon-free hepatitis C drug Qurevo (another trade name of Viekira Pak). It is produced specially for Egypt by the UK . Based on that, our study was conducted aiming to evaluate the efficacy and safety of Qurevo/ribavirin regimen in ESRD Egyptian patients on regular hemodialysis who are infected with HCV.
Patients and methods
This cohort study was conducted on 50 patients with end-stage renal disease, on regular hemodialysis with hepatitis C virus who received Qurevo/ribavirin regimen at the hepatic virology clinic at Ain Shams University hospital from December 2016 to February 2018.
Adults aged > 18 years old patients with end-stage renal disease (on regular hemodialysis), infected with hepatitis C virus with HCV RNA positivity, were included. They should have compensated liver (Child A cirrhosis or no cirrhosis), and Hb level is at least 10 g/dl with no associated uncontrolled co-morbidity (cardiac, neuro-psychiatric).
The following are the exclusion criteria: Child B and C cirrhosis patients; platelet count < 50,000/mm3; HCC, except 6 months after intervention aiming at cure with no evidence of activity by dynamic imaging (CT or MRI); and extra-hepatic malignancy except after 2 years of disease-free interval. In cases of lymphomas and chronic lymphocytic leukemia, treatment can be initiated immediately after remission based on the treating oncologist’s report. Pregnancy or inability to use effective contraception, also inadequately controlled diabetes mellitus (HbA1c > 9%).
All patients were subjected to full history taking (including renal condition and hepatitis C infection), full clinical examination and baseline laboratory investigations: CBC, serum creatinine, HCV Ab, HBsAg, PCR for HCV, liver functions “total and direct bilirubin/serum albumin/INR,” liver enzymes “AST/ALT,” alpha feto protein, and pelvi-abdominal ultrasound.
Treatment with daily fixed-dose combination of 2 tabs Qurevo “paritaprevir (75 mg, NS3/4A protease inhibitor)/ritonavir (50 mg)/ombitasvir (12.5 mg, NS5A inhibitor)” with meal + 200 mg ribavirin daily for 12 weeks was given, tracing the incidence of adverse events according to checklist and follow-up CBC, liver enzymes, and liver functions at weeks 4, 8, and 12 of treatment were done. PCR for HCV was repeated at 12 and 24 weeks after cessation of treatment to determine the SVR12.
The following are the definition of treatment responses:
Patients were regarded as having a rapid virologic response (RVR) when serum HCV RNA was undetectable at 4 weeks of treatment.
Patients who were negative for HCV RNA at 12 weeks after the completion of treatment were considered to have achieved sustained virologic response (SVR 12) .
Non-responders are patients who failed to clear HCV RNA from serum after 12 weeks of therapy, but as the protocol followed in our hospital did not include a PCR test at end of treatment, non-responders were considered those who did not achieve a negative PCR 12 weeks after therapy, that is to say, a SVR.
Relapsers are patients with the reappearance of HCV RNA in serum after achieving SVR12.
Statistical analysis was done on a personal computer using the Statistical Package for Social Sciences (IBM SPSS version 17. 0).
Descriptive statistics: mean, standard deviation [SD], range for numerical data, frequency, and percentage of non-numerical data.
Paired t-test: unpaired Student T-test was used to compare between related sample
Chi-square: the hypothesis that the row and column variables are independent, without indicating the strength or direction of the relationship. Pearson chi-square and likelihood ratio are used to compare the qualitative variables.
So, P-value is used as the level of significance: P-value > 0.05 is non-significant, P-value ≤ 0.05 is significant, and P-value < 0.01 is highly Significant.
The sample included 50 patients with end-stage renal disease on regular hemodialysis with hepatitis C virus who received Qurevo/ribavirin regimen at the hepatic virology clinic at Ain Shams University hospital from December 2016 to February 2018.
Table 1 shows the demographic data and clinical characteristics of the study group (50 patients). As regards the co-morbidities, hypertension was the most common (56%), diabetes in (26%), then ischemic heart disease (8%). Other comorbidities included cerebral palsy and rheumatoid arthritis in 2 subjects (4%). As regards Child score calculation, it was mainly A5 in 42 patients (84%) while A6 was in 8 patients (16%). But liver ultrasound was normal in 22 patients (44%) and showed abnormal hepatic echopattern in 17 patients (34%) and coarse hepatic echopattern in 11 patients (22%). The Child–Pugh score has been widely used to assess the severity of liver dysfunction in clinical work .
Table 2 shows that there was a highly significant progressive decline in the mean Hgb levels starting from week 4 (12.05 g/dl) to week 12 (8.959 g/dl) (P < 0.001), progressive rise of platelet counts although non-significant from a mean of 208.82 × 103/ml at baseline to 229.38 × 103/ml at week 12 with a delta change of 20.560 ± 86.368 (P = 0.099). There was a significant rise in total bilirubin throughout the study (P = 0.001, 0.023, 0.012 at weeks 4, 8, 12, respectively) with a progressive decline in direct bilirubin, together with an improvement of the INR being significant at week 12 (P = 0.048, P = 0.03, respectively). As regards liver enzymes, there was a significant decline in ALT throughout the study and a significant decline in AST at week 8 (P = 0.046).
Table 3 shows the response of the studied group to antiviral therapy. SVR 12 occurred in 48 out of 50 patients (96%). The PCR of another 2 patients turned positive after SVR12 (considered relapsers).
Table 4 shows that all 4 patients who had ribavirin reduced or stopped had negative PCR at week 24 (SVR12 rate 100%). So, there was no statistical correlation between them. This means that ribavirin dose reduction or discontinuation due to anemia did not affect the SVR12 rate.
Table 5 shows that the most common side effects were fatigue and asthenia in 44 patients (88%), anemia (Hb dropped to < 10 g/dl) in 42 patients (84%), GIT upset in 10 patients (20%), sleep disorders and decreased appetite in 8 patients (16%) each, and respiratory distress and headache with dizziness in 6 patients (12%) each, followed by muscle spasms in 4 patients (8%) and pruritis in 3 patients (6%).
Death occurred, after week 36 and within the 60 weeks of follow-up of the study, in 4 patients (8%) due to myocardial infarction, pulmonary edema, severe hypotension on hemodialysis sessions, and shock due to blood loss in retroperitoneal hematoma following peritoneal dialysis, most probably and was not related to DAA therapy. It occurred after a negative SVR 12 and SVR24.
Hepatic decompensation, hypersensitivity (angioedema), teratogenicity, and drug interactions did not occur in any patient (0%).
Other events occurred in 11 patients (22%). They were parenchymal liver changes in ultrasound at the end of therapy after being normal before therapy (in 3 patients), thrombocytopenia, increased alkaline phosphatase, hiccough, deterioration of hypertension, urinary tract infection, lower limb cellulitis, vaginal bleeding, and chest infection (in 1 patient each).
Table 6 shows the managements of patients with hemoglobin drop to < 10 g/dl.
Table 7 shows no significant correlation between reduced or stopped ribavirin and relapse or non-response to treatment.
Table 8 shows no statistically significant correlation between HCV viral load and failure of treatment.
The worldwide burden of HCV is estimated at 185 million out of which 12 million Egyptians suffer from HCV. Known to us is the morbidity of HCV as a leading cause of cirrhosis, hepatocellular carcinoma, and also known to us are the hepatorenal effects of HCV eventually leading to a higher rate of mortality among hemodialysis patients in specific. Hemodialysis has been identified as a separate risk factor for contracting HCV and taking into account the limited access of antiviral drugs due to the known toxicity of traditional HCV treatment on dialysis patients, new DAAs appeared as a better choice with ribavirin in those patients namely Qurevo ombitasvir/paritaprevir/ritonavir [9,10,11,12,13].
Our results revealed, regarding the efficacy, our SVR12 rate was 96% (48/50); 2 patients had virologic failure. This goes in line with the RUBY-I and RUBY-II trials presented at the meeting of the American Association for the Study of Liver Diseases (AASLD) held in Boston in November 2016, in which the SVR12 rate was 96% (46/48) in RUBY-I  and 94% (17/18) in RUBY-II by Gane et al. . Also, like the study in Japan by Atsukawa et al. , SVR12 rate was 96.8% (30/31), and like study in Egypt by Hanno et al. , SVR12 was also 96% (48/50). It was similar to a study in the USA by Lawitz et al. , the SVR12 rate was 95% (63/66), and in another study in Japan by Arai year 2018, SVR12 was 98.7%.
As regards the safety and adverse events, the most frequent were fatigue/asthenia in 44 patients (88%) and worsening anemia (Hb dropped to < 10 g/dl) in 42 patients (84%). GIT upset occurred in 10 patients (20%), sleep disorders in 8 patients (16%), decreased appetite in 8 patients (16%), respiratory distress in 6 patients (12%), and headache and dizziness in 6 patients (12%). Muscle spasms in 4 patients (8%). Itching (pruritis) occurred in 3 patients (6%). Two patients (4%) were non-responders to treatment, and another 2 (4%) were relapsers. Death was reported in 4 patients (8%), post-treatment probably unrelated to treatment, due to myocardial infarction, pulmonary edema, severe hypotension on hemodialysis sessions, and shock due to blood loss in retroperitoneal hematoma following peritoneal dialysis. Hepatic decompensation, hypersensitivity (angioedema), teratogenicity, and drug interactions did not occur in any patient (0%). Other events occurred in 11 patients (22%)% during therapy, not yet proved to be related or not to the drug. They were parenchymal liver changes in ultrasound at the end of therapy, after being normal before therapy (in 3 patients), thrombocytopenia, increased alkaline phosphatase, hiccough, deterioration of hypertension, urinary tract infection, lower limb cellulitis, vaginal bleeding, and chest infection (in 1 patient each). These results go in line with the RUBY-I trial  and Lawitz et al.  study in the USA, in which anemia was the most common adverse event. But, unlike the study of Atsukawa et al.  in Japan, which used a ribavirin-free regimen, and Hanno et al.  in Egypt, which enrolled different CKD stages (2–5) in which pruritis was the most common adverse event.
As regards follow-up CBC, liver enzymes, and liver functions in weeks 4, 8, and 12, we found that HGB levels decrease, total and indirect bilirubin increase due to ribavirin (RBV)-associated hemolysis , and AST, ALT, and INR levels decrease. This is in agreement with Hanno et al.  study in Egypt.
As regards anemia being the most common adverse event, several studies including ours confirm 2 observations. First, anemia during HCV treatment occurs higher with more advanced renal failure (more in CKD 5 dialysis patients than CKD 2–5 than non-CKD) shown by Osinusi et al. . Second, it occurs in the majority of the studies with ribavirin including regimens. This was obvious in our study which included both advanced renal failure, ESRD patients on regular hemodialysis, and ribavirin including regimen.
To overcome anemia in ESRD receiving HCV therapy, ribavirin dose is 200 mg/day (typically starting at 200 mg three times weekly and titrating up to 200 mg/day as tolerated). Ribavirin should be discontinued if the hemoglobin level decreases by more than 2 g/dl despite the use of erythropoietin according to (AASLD) guidelines . SVR12 rate in our study was achieved in 100% of patients who had to stop or modify RBV dose; this means that RBV absence did not affect the SVR12 in these patients. This leads us to think of RBV-free regimens in ESRD patients as a safer option of treatment to avoid severe hemolytic anemia with ribavirin that occurs with these patients despite various anemia managements during therapy.
The current guidelines recommend two ribavirin-free regimens for patients with HCV infection and stage 4 or 5 CKD, elbasvir/grazoprevir, which is approved for the treatment of patients with GT1 or 4 infection, and glecaprevir/pibrentasvir, which has pan-genotypic activity. Both show high efficacy (SVR12) with no anemia as adverse event in ESRD. For this reason, the regimen used in our study ombitasvir/paritaprevir/ritonavir and ribavirin would be considered to be alternatives to the 2 recommended regimens . However, these 2 regimens are not yet available in Egypt.
There were several limitations in our study. First, we could not study the effect of our drug on CKD staging because our patients were all ESRD, CKD 5 on regular hemodialysis. Second, ribavirin caused hemolytic anemia, which was an inconvenient adverse event. Third, only 4 patients had to stop or modify RBV which was a small number. So, we could not draw a firm conclusion about RBV-free ombitasvir/paritaprevir/ritonavir regimen as being effective alone in the treatment of HCV. Fourth, our study had 2 virologic failures and 2 relapses. We correlated between them and RBV dose modification and also HCV viral load but there was no statistically significant relation. It was difficult to know the exact causes of failure of treatment and relapse due to a small number of them. However, other studies attribute the cause to resistance-associated substitutions in the NS3/4A region before treatment. For instance, Q80K shows a threefold resistance to paritaprevir (NS3/4A protease inhibitor). The detection rate of pre-existing D168 substitution is also found . Fifth, we did not do genotyping on the patients assuming that genotype 4 is the most common variant of HCV throughout Egypt and represents more than 90% of HCV isolates from Egyptian patients . So, we could not study the effect of our drug in different HCV genotypes (1–6) However, it is obvious that our drug shows high efficacy in genotype 4 assuming that most HCV Egyptians have genotype 4.
Our results confirm the efficacy of Qurevo “ombitasvir/paritaprevir/ritonavir” with ribavirin combination therapy in ESRD patients on regular hemodialysis with HCV infection, with anemia as the most frequent adverse event.
The following are the recommendations:
We recommend Qurevo (ombitasvir/paritaprevir/ritonavir) with ribavirin regimen.
For ESRD patients with HCV infection.
We also recommend monitoring of hemoglobin and total bilirubin levels at weeks 4, 8, and 12 for early detection of anemia or hepatic decompensation which may lead to drug discontinuation and as a result we highly recommend RBV-free new regimens in ESRD patients like elbasvir/grazoprevir or glecaprevir/pibrentasvir as a safer option of treatment to avoid severe hemolytic anemia with RBV that occurs with ESRD patients.
A specialized hepatologist and nephrologist should be found in hepatic virology clinics to help ESRD patients plan the most suitable HCV antiviral drug regimen for each patient.
Studies should be done on qualitative HCV genotyping to detect exact causes of virologic failure/relapse with the drug (resistance-associated substitutions in the NS3/4A region before treatment, e.g., presence of Q80K and pre-existing D168 substitution).
Availability of data and materials
Please contact the authors for data requests.
World Health Organization
Hepatitis C virus
End-stage renal disease
Chronic kidney disease
Direct-acting antiviral agents
Human immunodeficiency virus
Polymerase chain reaction
American Association for the Study of Liver Diseases
International normalization ratio
Sustained virologic response after 12 weeks
Sustained virologic response after 24 weeks
Fabrizi F, Messa P, Martin P et al (2014) Recent advances on hepatitis C virus in dialysis population. Kidney Blood Press Res 39:260–271
Azmi AN, Tan SS, Mohamed R (2015) Hepatitis C and kidney disease: An overview and approach to management. World J Hepatol. 7(1):78–92. https://doi.org/10.4254/wjh.v7.i1.78
Messa P, Fabrizi F (2015) Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population. Expert Rev ClinPharmacol 8:785–793
Gilead and Bristol-Myers Squibb (2016) Adverse effects of ombitasvir, paritaprevir, ritonavir. Gastroenterology 37:473–481
Janssen, Pockros P, Merck et al (2016) Study of ombitasvir, paritaprevir, ritonavir in patients with chronic hepatitis C virus. Gastroenterology 16:1345–7
Raedler LA (2015) Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets) all-oral fixed combination approved for chronic hepatitis C infection. Am Health Drug Benefits 8:142–147
Jacobson IM, Poordad F, Brown Jr RS, KwoPY, Reddy KR, Schiff E (2012) Standardization of terminology of virological response in the treatment of chronic hepatitis C: panel recommendations. J Viral Hepat 19:236–43
Ho CH, Chiang CL, Lee FA et al (2018) Comparison of platelet-albumin-bilirubin (PALBI), albumin-bilirubin (ALBI), and Child-Pugh (CP) score for predicting of survival in advanced HCC patients receiving radiotherapy (RT). Oncotarget 9(48):288–292
Hajarizadeh B, Grebely J, Dore GJ (2018) Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 10(9):553–62
Kamal SM, Abdelhakam SA (2018) Hepatitis C in Egypt. Curr Future Chall 14:41–56
Davis GL, Ocean Grande and Ponte Vedra Beach, AASLD/IDSA (2015) Recommendations for testing, management, and treating hepatitis C. Unique patient populations: patients with renal impairment [AASLD/IDSA Hepatitis C Guidance]. Hepatology 62:932–954
Agarwal SK, Bagchi S, Yadav RK (2017) Hemodialysis patients treated for hepatitis C using a sofosbuvir-based regimen. Kidney Int Rep 2(5):831–835
Bunchorntavakul C, Maneerattanaporn M, Chavalitdhamrong D (2015) Management of patients with hepatitis C infection and renal disease. World J Hepatol 7:213–225
Vierling JM, Lawitz E, Reddy KR et al (2016) RUBY-I: safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in adults with genotype 1 chronic hepatitis C virus (HCV) infection with severe renal impairment or end-stage renal disease. Hepatology 64:886
Gane EJ, Sola R, Cohen E et al (2016) RUBY-II: efficacy and safety of a ribavirin-free ombitasvir/paritaprevir/ritonavir ± dasabuvir regimen in patients with severe renal impairment or end-stage renal disease and HCV genotype 1a or 4 infection. Hepatology 64:935
Atsukawa M, Tsubota A, Koushima Y et al (2017) Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. Hepatol Res 47(13):1429–1437
Hanno A, Elwazzan D, Ibrahim M et al (2018) Real life study of ombitasvir/paritaprevir/ritonavir in chronic kidney disease Egyptian patients infected with HCV genotype 4. Gut Gastroenterol 1:001–006
Lawitz E, Gane E, Cohen E et al (2018) Efficacy and safety of ombitasvir/paritaprevir/ritonavir in patients with hepatitis C virus genotype 1 or 4 infection and advanced kidney disease. Kidney Int Rep 1:1–28
Zeuzem S, Jacobson IM, Baykal T et al (2014) Retreatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin. N Engl J Med 370:1604–1614
Osinusi A, Meissner EG, Lee YJ et al (2013) Efficacy of Sofosbuvir and ribavirin for treatment of hepatitis C genotype-1 in an inner city population: virus and host factors that predict relapse. JAMA 310:804–811
Pilot Matias T, Tripathi R, Cohen D et al (2015) In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 59:988–997
Kamel MA, Miller FD, El Masry AG et al (2013) The epidemiology of Schistosoma mansoni, hepatitis B and hepatitis C infection in Egypt. Ann Trop Med Parasitol 88:501–509
This was self-funded by the authors.
Ethics approval and consent to participate
This study has conformed with the ethics committee of the hospital and according to the Declaration of Helsinki for ethical principles WMA.
Consent for publication
Not applicable (no personal data of patients included).
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Elshinnawy, H.A.E., Sarhan, I.I., Ahmed, O.A. et al. Study the response of Qurevo (ombitasvir, paritaprevir, and ritonavir) in end-stage renal disease patients with hepatitis C virus. Egypt Liver Journal 12, 36 (2022). https://doi.org/10.1186/s43066-022-00196-x
- Hepatitis C virus
- End-stage renal disease